- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03543397
MRI in Ductal Carcinoma in Situ (DCIS)
May 31, 2018 updated by: University Hospital, Strasbourg, France
Relevance of Mammary MRI in the Preoperative Assessment of Ductal Carcinoma in Situ (DCIS)
Compare the estimate of the lesional size in MRI to that in mammography, taking as a reference the definitive anatomo-pathological size
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
74
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marie Noëlle ROEDLICH, MD
- Phone Number: 33 3 88 12 78 42
- Email: marie-noelle.roedlich@chru-strasbourg.fr
Study Contact Backup
- Name: Claire DETTLOFF, MD
- Phone Number: 33 3 88 12 78 42
- Email: claire.dettloff@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67098
- Recruiting
- Service de Radiologie 1
-
Contact:
- Marie Noëlle ROEDLICH, MD
- Phone Number: 33 3 88 12 78 42
- Email: marie-noelle.roedlich@chru-strasbourg.fr
-
Contact:
- Claire DETTLOFF, MD
- Phone Number: 33 3 88 12 78 42
- Email: claire.dettloff@chru-strasbourg.fr
-
Principal Investigator:
- Marie Noëlle ROEDLICH, MD
-
Sub-Investigator:
- Claire DETTLOFF, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Woman with DCIS
Description
Inclusion Criteria:
- Age ≥18 ans
- Woman with DCIS
Exclusion Criteria:
- Age ≥18 ans)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The investigators compare the estimate of the lesional size in MRI to that in mammography, taking as a reference the definitive anatomo-pathological size
Time Frame: The period from January 1st, 2017 to December 31st, 2017 will be examined]
|
Patients hospitalized at Strasbourg University Hospital in 2017
|
The period from January 1st, 2017 to December 31st, 2017 will be examined]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Marie Noëlle ROEDLICH, MD, University Hospital, Strasbourg, France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 26, 2018
Primary Completion (Anticipated)
February 1, 2019
Study Completion (Anticipated)
February 1, 2019
Study Registration Dates
First Submitted
February 26, 2018
First Submitted That Met QC Criteria
May 31, 2018
First Posted (Actual)
June 1, 2018
Study Record Updates
Last Update Posted (Actual)
June 1, 2018
Last Update Submitted That Met QC Criteria
May 31, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ductal Carcinomas
-
M.D. Anderson Cancer CenterRecruitingRenal Medullary Carcinoma | CarcinomasUnited States
-
Cook Group IncorporatedCompletedCarcinomas/NeoplasmsCanada, United States, France, Netherlands
-
Gustave Roussy, Cancer Campus, Grand ParisUnknown
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingBreast Ductal Carcinoma In SituUnited States, Canada, Puerto Rico, Korea, Republic of
-
Xoft, Inc.Icad, Inc.WithdrawnDuctal Carcinoma In Situ | Invasive Ductal Carcinoma
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditionsUnited States
-
St. Joseph Hospital of OrangeActive, not recruitingInvasive Lobular and Ductal CarcinomaUnited States
-
Yale UniversityPatient-Centered Outcomes Research InstituteCompletedDuctal Carcinoma In SituUnited States
-
Sunnybrook Health Sciences CentreTerminated
-
Windy Hill Medical, Inc.UnknownDuctal Carcinoma In SituUnited States